Fusion Antibodies (LSE:FAB) EV-to-EBIT : -1.06 (As of May. 25, 2024)

Fusion Antibodies EV-to-EBIT Chart

Fusion Antibodies Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
EV-to-EBIT		Get a 7-Day Free Trial				-2.98	-18.83	-30.30	-10.29	-3.47

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial											-	-10.29	-	-3.47	-

Competitive Comparison of Fusion Antibodies's EV-to-EBIT

For the Biotechnology subindustry, Fusion Antibodies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's EV-to-EBIT falls into.

Fusion Antibodies EV-to-EBIT Calculation

Fusion Antibodies's EV-to-EBIT for today is calculated as:

Fusion Antibodies's current Enterprise Value is £3.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies  (LSE:FAB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fusion Antibodies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Fusion Antibodies's Enterprise Value for the quarter that ended in Sep. 2023 was £2.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description